{"log_id": 6692479434983142029, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0.000273, "average": 0.983473, "min": 0.966951}, "location": {"width": 24, "top": 137, "height": 77, "left": 1119}, "words": "一药"}, {"probability": {"variance": 6.8e-05, "average": 0.996434, "min": 0.949273}, "location": {"width": 774, "top": 213, "height": 32, "left": 197}, "words": "(单用或与其他药物酒精合用),在大多数报告中摄入量不超过日常剂量的数倍。摄入最高"}, {"probability": {"variance": 0.002596, "average": 0.983362, "min": 0.659021}, "location": {"width": 779, "top": 259, "height": 30, "left": 192}, "words": "剂量的3例患者摄入量估计约为6.75g、2.75g和2.5g,后两例患者的文拉法辛血浆峰浓度分别"}, {"probability": {"variance": 0.008225, "average": 0.956438, "min": 0.565911}, "location": {"width": 776, "top": 303, "height": 33, "left": 195}, "words": "为6.24和2.35μg/mL,0去甲基文拉法辛的血浆峰浓度分别为3.37和130gmL。无摄入量为"}, {"probability": {"variance": 0.001083, "average": 0.990599, "min": 0.800209}, "location": {"width": 781, "top": 348, "height": 34, "left": 189}, "words": "675g的患者的血浆文拉法辛浓度报道,14例患者痊愈后均无后遗症。大多数患者没有任何"}, {"probability": {"variance": 0.018571, "average": 0.951859, "min": 0.437854}, "location": {"width": 761, "top": 394, "height": 34, "left": 191}, "words": "症状,在其他患者中、嗜睡是最常见的不良反应。患者摄入量为2.15时,观察到两例抽搐"}, {"probability": {"variance": 0.011488, "average": 0.967262, "min": 0.367383}, "location": {"width": 712, "top": 440, "height": 32, "left": 213}, "words": "例Q间隔延长为500毫秒(基线值为450毫秒),另有两例轻度窦性心动过速的报遒"}, {"probability": {"variance": 0.000424, "average": 0.991678, "min": 0.910004}, "location": {"width": 733, "top": 484, "height": 34, "left": 238}, "words": "在文拉法辛上市后的使用中,文拉法辛药物过量多与其它药物酒精合用有关。药物过"}, {"probability": {"variance": 0.007935, "average": 0.973823, "min": 0.518724}, "location": {"width": 778, "top": 530, "height": 32, "left": 193}, "words": "量最常报告的事件包括心动过速、意识水平改变(从嗜睡到昏迷)、瞳孔扩大、癫痫发作和"}, {"probability": {"variance": 0.003988, "average": 0.969715, "min": 0.71895}, "location": {"width": 764, "top": 574, "height": 32, "left": 193}, "words": "呕吐。其它报告的事件包括心电图变化(例如,QT间期延长、束支性传导阻滞和QRS延长)"}, {"probability": {"variance": 1e-06, "average": 0.998876, "min": 0.997423}, "location": {"width": 119, "top": 624, "height": 23, "left": 195}, "words": "室性心动过速"}, {"probability": {"variance": 0.000153, "average": 0.993376, "min": 0.942459}, "location": {"width": 603, "top": 619, "height": 28, "left": 356}, "words": "动过缓、低血压、横纹肌溶解、眩晕、肝坏死、5羟色胺综合征和死亡"}, {"probability": {"variance": 0.002361, "average": 0.981208, "min": 0.765167}, "location": {"width": 733, "top": 664, "height": 29, "left": 238}, "words": "回顾性研究报告,与5-羟色胺再摄取抑制剂(SSRI)类抗抑郁药中观察到的相比,文"}, {"probability": {"variance": 0.000117, "average": 0.995029, "min": 0.945966}, "location": {"width": 780, "top": 707, "height": 33, "left": 193}, "words": "拉法辛过量可能与致死风险的升高有关,但其过量引起的致死风险较三环类抗抑郁药低。流"}, {"probability": {"variance": 0.000244, "average": 0.993181, "min": 0.90649}, "location": {"width": 760, "top": 753, "height": 32, "left": 194}, "words": "行病学研究显示,与使用SSR的患者相比,使用文拉法辛的患者存在较高的自杀风险因素"}, {"probability": {"variance": 0.010379, "average": 0.976101, "min": 0.392785}, "location": {"width": 774, "top": 798, "height": 31, "left": 198}, "words": "文拉法辛过量导致死亡的风险增加归于过量所产生的毒性以及使用文拉法辛的患者群的"}, {"probability": {"variance": 0.000136, "average": 0.993751, "min": 0.953992}, "location": {"width": 778, "top": 842, "height": 31, "left": 195}, "words": "某些特质,但其程度尚不清楚。医生在处方文拉法辛时应给予最小包装量(即盒数)的药"}, {"probability": {"variance": 2.7e-05, "average": 0.997879, "min": 0.973254}, "location": {"width": 511, "top": 887, "height": 31, "left": 196}, "words": "物,同时对患者进行有效管理,以减少文拉法辛过量的危险"}, {"probability": {"variance": 1e-06, "average": 0.999024, "min": 0.996225}, "location": {"width": 144, "top": 935, "height": 25, "left": 195}, "words": "药物过量的处理"}, {"probability": {"variance": 0.000719, "average": 0.992877, "min": 0.837805}, "location": {"width": 713, "top": 975, "height": 32, "left": 260}, "words": "般处理措施与其它抗抑郁药过量相似,保证气道通畅和适当的吸氧和换气,监测心"}, {"probability": {"variance": 0.000577, "average": 0.992744, "min": 0.854054}, "location": {"width": 774, "top": 1021, "height": 31, "left": 197}, "words": "率和生命体征,采用一般性的支持和对症治疗。如有吸入风险,不推荐采用催吐,对于出现"}, {"probability": {"variance": 0.009208, "average": 0.974798, "min": 0.506883}, "location": {"width": 772, "top": 1064, "height": 31, "left": 199}, "words": "症状或服药不久的患者可进行洗胃,洗宵时保持呼吸道通畅。可考虑使用活性碳(可限制药"}, {"probability": {"variance": 2.2e-05, "average": 0.997361, "min": 0.979489}, "location": {"width": 775, "top": 1108, "height": 31, "left": 198}, "words": "物的吸收)。因为药物有较大的分布容积,强利尿、透析、血液灌注以及换血疗法可能疗效"}, {"probability": {"variance": 0, "average": 0.99931, "min": 0.998714}, "location": {"width": 45, "top": 1158, "height": 24, "left": 198}, "words": "不大"}, {"probability": {"variance": 1.1e-05, "average": 0.998072, "min": 0.987713}, "location": {"width": 314, "top": 1200, "height": 26, "left": 245}, "words": "本品药物过量目前尚无特殊的解毒药"}, {"probability": {"variance": 3e-05, "average": 0.997799, "min": 0.968477}, "location": {"width": 729, "top": 1241, "height": 31, "left": 244}, "words": "处理药物过量时,应考虑到同时服用多种药物的可能,医生应联系毒物控制中心获取"}, {"probability": {"variance": 0.000835, "average": 0.984576, "min": 0.920097}, "location": {"width": 122, "top": 1292, "height": 25, "left": 198}, "words": "进一步的信息"}, {"probability": {"variance": 0.000443, "average": 0.985326, "min": 0.946701}, "location": {"width": 110, "top": 1336, "height": 24, "left": 205}, "words": "【药理毒理】"}, {"probability": {"variance": 1e-06, "average": 0.99897, "min": 0.997539}, "location": {"width": 82, "top": 1381, "height": 23, "left": 200}, "words": "药理作用"}, {"probability": {"variance": 0.006165, "average": 0.962304, "min": 0.696179}, "location": {"width": 729, "top": 1419, "height": 32, "left": 244}, "words": "非临床研究显示,文拉法辛及其活性代谢物0-去甲基文拉法辛是5-T、NE再摄取的强"}, {"probability": {"variance": 0.004282, "average": 0.979182, "min": 0.664636}, "location": {"width": 773, "top": 1464, "height": 32, "left": 200}, "words": "抑制剂,是多巴胺再摄取的弱抑制剂。体外试验未发现文拉法辛及O去甲基文拉法辛对M胆"}, {"probability": {"variance": 0.009437, "average": 0.96404, "min": 0.588489}, "location": {"width": 775, "top": 1507, "height": 32, "left": 199}, "words": "碱受体、H1组胺受体、01-肾上腺素能受体有明显的亲和力。文拉法辛及O-去甲基文拉法"}], "language": 3}